

SCOPE: ALS, CCT	
<b>MEDICATION:</b>	<b>LIDOCAINE HYDROCHLORIDE 2% (Xylocaine)</b>
<b>INTERVENTION:</b>	<p><u>Classification:</u> Antiarrhythmic, Anesthetic</p> <p><u>Actions:</u> Blocks both initiation and conduction of nerve impulses which results in local anesthesia; Increases ventricular electrical threshold, suppressing ventricular arrhythmias and terminating re-entrant ventricular arrhythmias; stabilizes cardiac tissue and decreases automaticity; Blunts transient increases in intracerebral pressure during intubation in the presence of a head injury</p> <p><u>Contraindications:</u></p> <ul style="list-style-type: none"> <li>• Hypersensitivity to lidocaine</li> <li>• Wolff-Parkinson-White (WPW) syndrome or Adam-Stokes syndrome</li> <li>• Severe degrees of SA, AV, or intraventricular heart block (except in patients with a functioning artificial pacemaker)</li> </ul> <p><u>Precautions:</u></p> <ul style="list-style-type: none"> <li>• Hepatic impairment, heart failure, marked hypoxia, severe respiratory depression, hypovolemia, history of malignant hyperthermia, or shock</li> <li>• Lactation</li> <li>• <b>PREGNANCY RISK FACTOR: B</b></li> </ul> <p><u>Dosage:</u></p> <ol style="list-style-type: none"> <li>I. <u>IO anesthesia:</u> <ol style="list-style-type: none"> <li>a. Adult:           <ol style="list-style-type: none"> <li>i. IO: 40 mg over 2 minutes               <ol style="list-style-type: none"> <li>1. May repeat 20 mg over 60 seconds, PRN</li> </ol> </li> </ol> </li> <li>b. Pediatric/Neonatal:           <ol style="list-style-type: none"> <li>i. IO: 0.5 mg/kg (max 40 mg) over 2 minutes               <ol style="list-style-type: none"> <li>1. May repeat 0.25 mg/kg (max 20 mg) over 60 seconds, PRN</li> </ol> </li> </ol> </li> </ol> </li> </ol> <p><u>Onset of Action:</u> Single bolus dose: 45-90 seconds</p> <p><u>Duration:</u> 10-20 minutes</p> <p><u>Adverse Effects:</u> Bradycardia, arrhythmia, circulatory shock, coronary artery vasospasm, edema, flushing, heart block, hypotension, local thrombophlebitis, respiratory depression, bronchospasm, dizziness, seizures, AMS/decreased LOC, nausea/vomiting</p> <p><u>Special Considerations:</u></p> <ol style="list-style-type: none"> <li>I. Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy</li> <li>II. Correct any underlying causes of ventricular arrhythmias. Monitor closely for signs and symptoms of CNS toxicity</li> <li>III. Max continuous infusion dose for patients with CHF, shock, or hepatic disease maximum is 1.5 mg/min (Adult) or 20 mcg/kg/min (Pediatric)</li> </ol>

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

<i>FOR OFFICE USE ONLY</i>	
Originator:	Original Date:
Revised Date:	
Effective Date: 06/01/18	Page 1 of 2

